Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of CM313 (SC) Injection in Subjects With IgA Nephropathy

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety and Efficacy of CM313 (SC) Injection in Subjects With IgA Nephropathy

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 313 (Primary)
  • Indications IgA nephropathy
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors KeyMed Biosciences

Most Recent Events

  • 26 Mar 2025 According to a Keymed Biosciences media release, company initiated a randomized, double-blinded, placebo-controlled Phase II clinical study of CM313(SC) injection in subjects with IgA nephropathy in early 2025. As of the date of this announcement, preparations for patient enrollment are underway for this study.
  • 21 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top